Amodiaquine-artesunate versus amodiaquine for uncomplicated Plasmodium falciparum malaria in African children: a randomised, multicentre trial

[1]  A. Mr.  Severe and complicated malaria. , 2002 .

[2]  P. Kremsner,et al.  Comparison of methods for the rapid laboratory assessment of children with malaria. , 2001, The American journal of tropical medicine and hygiene.

[3]  P. Olliaro,et al.  Acute asymptomatic hepatitis in a healthy normal volunteer exposed to 2 oral doses of amodiaquine and artesunate. , 2001, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[4]  P. Rosenthal,et al.  Amodiaquine, sulfadoxine/pyrimethamine, and combination therapy for treatment of uncomplicated falciparum malaria in Kampala, Uganda: a randomised trial , 2001, The Lancet.

[5]  P. Matsiegui,et al.  [Evaluation of efficacy and tolerance of amodiaquine versus chloroquine in the treatment of uncomplicated malaria outbreak in children of Gabon]. , 2001, Bulletin de la Societe de pathologie exotique.

[6]  P. Kremsner,et al.  Mosquito distribution and entomological inoculation rates in three malaria-endemic areas in Gabon. , 2000, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[7]  I. Edwards,et al.  Adverse drug reactions: definitions, diagnosis, and management , 2000, The Lancet.

[8]  Richard N. Price,et al.  Effects of artesunate-mefloquine combination on incidence of Plasmodium falciparum malaria and mefloquine resistance in western Thailand: a prospective study , 2000, The Lancet.

[9]  N. Gogtay,et al.  A randomized, double-blind, parallel-group, comparative safety, and efficacy trial of oral co-artemether versus oral chloroquine in the treatment of acute uncomplicated Plasmodium falciparum malaria in adults in India. , 2000, The American journal of tropical medicine and hygiene.

[10]  K. Bojang,et al.  Efficacy of artesunate plus pyrimethamine-sulphadoxine for uncomplicated malaria in Gambian children: a double-blind, randomised, controlled trial , 2000, The Lancet.

[11]  I S Chan,et al.  Test‐Based Exact Confidence Intervals for the Difference of Two Binomial Proportions , 1999, Biometrics.

[12]  R. Guiguemdé,et al.  Amodiaquine remains effective for treating uncomplicated malaria in west and central Africa. , 1999, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[13]  S. Hollis,et al.  What is meant by intention to treat analysis? Survey of published randomised controlled trials , 1999, BMJ.

[14]  N. White,et al.  Delaying antimalarial drug resistance with combination chemotherapy. , 1999, Parassitologia.

[15]  N. White,et al.  Efficacy of six doses of artemether-lumefantrine (benflumetol) in multidrug-resistant Plasmodium falciparum malaria. , 1999, The American journal of tropical medicine and hygiene.

[16]  R. Price,et al.  Risk factors for gametocyte carriage in uncomplicated falciparum malaria. , 1999, The American journal of tropical medicine and hygiene.

[17]  E. Lagarde,et al.  Impact of chloroquine resistance on malaria mortality. , 1998, Comptes rendus de l'Academie des sciences. Serie III, Sciences de la vie.

[18]  P. Kibatala,et al.  Efficacy and safety of CGP 56697 (artemether and benflumetol) compared with chloroquine to treat acute falciparum malaria in Tanzanian children aged 1–5 years , 1998, Tropical medicine & international health : TM & IH.

[19]  K. Bojang,et al.  A randomized controlled trial of artemether/benflumetol, a new antimalarial and pyrimethamine/sulfadoxine in the treatment of uncomplicated falciparum malaria in African children. , 1998, The American journal of tropical medicine and hygiene.

[20]  S. Jaffar,et al.  Treatment of African children with uncomplicated falciparum malaria with a new antimalarial drug, CGP 56697. , 1997, The Journal of infectious diseases.

[21]  P. Garner,et al.  Systematic review of amodiaquine treatment in uncomplicated malaria , 1996, The Lancet.

[22]  P. Olliaro,et al.  Strategies for the prevention of antimalarial drug resistance: rationale for combination chemotherapy for malaria. , 1996, Parasitology today.

[23]  P. Kremsner,et al.  Atovaquone and proguanil for Plasmodium falciparum malaria , 1996, The Lancet.

[24]  H. Contamin,et al.  PCR typing of field isolates of Plasmodium falciparum , 1995, Journal of clinical microbiology.

[25]  G. Luzzi,et al.  Adverse Effects of Antimalarials , 1993, Drug safety.

[26]  G. Shanks,et al.  The efficacy of pyrimethamine-sulfadoxine (Fansidar) in the treatment of uncomplicated Plasmodium falciparum malaria in Kenyan children. , 2000, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[27]  M. Newell.  Vertical transmission of HIV-1 infection. , 2000, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[28]  R. Snow,et al.  Estimating mortality, morbidity and disability due to malaria among Africa's non-pregnant population. , 1999, Bulletin of the World Health Organization.

[29]  C. Sokhna,et al.  Tests in vivo de chimiosensibilité de Plasmodium falciparum à la chloroquine au Sénégal : évolution de la résistance et estimation de l'efficacité thérapeutique , 1997 .

[30]  P. Phillips-Howard,et al.  Ascertainment of risk of serious adverse reactions associated with chemoprophylactic antimalarial drugs. , 1990, Bulletin of the World Health Organization.

[31]  C. Murray,et al.  Adult mortality in developing countries. , 1990, Transactions of the Royal Society of Tropical Medicine and Hygiene.